联合脐血或脐带间充质干细胞异基因移植术后观察

Transplantation of combined allogene,cord blood and mesenchymal stem cells

  • 摘要: 目的 观察联合脐血或脐带间充质干细胞(Mesenchym alStem Cell,MSC)的异基因造血干细胞移植的安全性、有效性及相关并发症发生情况。方法 15例联合脐血或脐带MSC的异基因造血干细胞移植患者与15例未联合脐血或脐带MSC的异基因造血干细胞移植患者进行造血免疫重建、骨髓植入水平、骨髓恢复及移植相关并发症比较。结果 实验组平均回输脐血或脐带间充质干细胞数为1.077×107/kg,移植过程顺利,血象恢复白细胞>0.5×109/L平均13.07d,血小板>20×109/L平均13.6d,较对照组血象恢复快(P<0.05)。实验组较对照组严重广泛性慢性移植物抗宿主病(cGVHD)发生率低(P<0.05),但两组之间aGVHD、肺部及病毒感染、1年复发率、死亡率比较无统计学意义(P>0.05)。结论 联合脐血或脐带MSC的异基因造血干细胞移植成功率高,如何提高1年总生存率值得进一步研究。

     

    Abstract: Objective To observe the security,efficiency and related complications of transplantation of combined allogeneic hematopoietic stem cells,cord blood and mesenchymal stem cells(MSC). Methods Hematopoietic immunity was reconstructed in 15 patients undergoing transplantation of combined allogeneic hematopoietic stem cells,cord blood and MSC,and in 15 patients not undergoing transplantation of cord blood or MSC.Implantation level and recovery of bone marrow,and transplantation-related complications were compare(dP<0.05). Results In the experimental group,the average speed of re-infusing cord blood was faster with the MSC count of 1.077×107/kg,and the transplantation was uneventful.The number of white blood cells and platelets was over 0.5×109/L and 20×109/L,respectively,during an mean recovery period of 13.07d and 13.6d,which were much more that that in control group(P<0.05).The incidence of severe massive chronic graft versus host disease(GVHD) was lower in experimental group than in control group(P<0.05).However,no statistical difference was observed in chronic GVHD,lung infection,virus infection,1-year relapse and mortality between the two groups. Conclusion A high success rate can be achieved in transplantation of combined allogeneic hematopoietic stem cells,cord blood and MSC and how to increase the 1-year survival rate of patients should be further studied.

     

/

返回文章
返回